Enzalutamide in elderly patients with mCRPC: a clinical experience
10.3760/cma.j.cn112330-20210908-00013
- VernacularTitle:恩扎卢胺在高龄mCRPC患者中的应用经验
- Author:
Shaoan CHEN
1
;
Xiaohai WANG
;
Bangmin HAN
Author Information
1. 上海交通大学医学院附属上海市第一人民医院泌尿外科，上海 200080
- Keywords:
Enzalutamide;
Metastatic castration-resistant prostate cancer;
Endocrine therapy
- From:
Chinese Journal of Urology
2021;42(Z2):43-46
- CountryChina
- Language:Chinese
-
Abstract:
As the end-stage of prostate cancer, metastatic castration-resistant prostate cancer(mCRPC) complicates the disease and therefore challenges the doctors. In October 2018, an 87-year-old patient diagnosed with metastatic prostate cancer was admitted to Shanghai General Hospital for evaluation and treatment. Poor basic health condition plus severe side effect resulted in patient’s poor compliance with treatment and irregular follow-up. The patient progressed to mCRPC in September 2020, and was given enzalutamide as first-line therapy, after which the patient’s PSA level was under control with no side effect.
